Milestone Pharmaceuticals reported Q3 2026 financial results, highlighting $1.0 million in net product revenue for CARDAMYST and a 73% increase over the prior quarter. The company announced a 30% reduction in operating expenses, including leadership departures and bringing its sales force in-house, to extend its cash runway into late 2028. This extension is designed to fund operations through the anticipated Phase 3 data readout for etripamil in AFib-RVR expected in 2H 2028.
Term
Q3 2026
“We are encouraged by the early progress of CARDAMYST, and as we gain experience in the market, we believe we are better able to identify where our investments can have the greatest potential impact. The actions we are announcing today reflect a more efficient approach to capital allocation, which we believe will drive continued prescription growth, expand our prescriber base and improve patient access for CARDAMYST, while reducing operating expenses.”
Joseph Oliveto, President and Chief Executive Officer
Milestone Pharmaceuticals reported a significant increase in cash and cash equivalents to $144.5 million as of September 30, 2026, following the recognition of an $82.8 million royalty financing obligation. The company's accumulated deficit grew to $511.1 million, reflecting ongoing development and commercialization preparations for CARDAMYST (etripamil) nasal spray.
Milestone Pharmaceuticals received a deficiency notice from Nasdaq on October 23, 2026, because its common shares failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has until April 21, 2027, to regain compliance by having its shares close at $1.00 or higher for at least 10 consecutive business days.